Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GW Pharma’s Cannabidiol For Seizures One Step Closer To European Approval

Executive Summary

The CHMP has issued a positive opinion for Epidyolex for two rare conditions. The cannabidiol product was approved in the US in 2018.

You may also be interested in...



Pain Relief Most Popular Reason For Using CBD In UK

Pain relief is by far the most popular reason for taking CBD in the UK, a recent survey has revealed. The research by YouGov also finds that a quarter of those who have not tried CBD are tempted to do so. 

Slovakia Down-Schedules CBD As WHO Insists It Is Not A Narcotic

As a recent meeting of the United Nation's Commission on Narcotic Drugs, the World Health Organization recommended that CBD products with no more than 0.2% THC should not be considered controlled substances. In response, Slovakia down-scheduled CBD. The move and the discussion sparked by WHO's recommendation within the UN 's drug commission shines a new light on debates raging in the UK, where industry is currently facing claims that CBD products with any levels of THC whatsoever should be considered a controlled substance.

Titans Of Pharma 2020: 15 Leading CEOs Bag $266m In Compensation

See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.

Topics

Related Companies

UsernamePublicRestriction

Register

AG002833

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel